José Luís Molinuevo
A5036068671- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- Health, Environment, Cognitive Aging
- Advanced Neuroimaging Techniques and Applications
- Neurological Disease Mechanisms and Treatments
- Parkinson's Disease Mechanisms and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Neuroinflammation and Neurodegeneration Mechanisms
- Bioinformatics and Genomic Networks
- Cholinesterase and Neurodegenerative Diseases
- Neurological disorders and treatments
- Memory and Neural Mechanisms
- Genetics, Aging, and Longevity in Model Organisms
- Neurological diseases and metabolism
- Diet and metabolism studies
- Blood Pressure and Hypertension Studies
- Neurobiology of Language and Bilingualism
- Cancer-related cognitive impairment studies
- Sleep and Wakefulness Research
- Nutritional Studies and Diet
- Neuroscience and Neuropharmacology Research
- Medical Imaging Techniques and Applications
- Genetic Associations and Epidemiology
- Sleep and related disorders
Pasqual Maragall Foundation
2016-2025
Barcelonaβeta Brain Research Center
2016-2025
Lundbeck (Spain)
2025
Lundbeck (Denmark)
2021-2024
Forschungszentrum Jülich
2024
University Hospital Cologne
2024
University of Cologne
2022-2024
University of Brescia
2024
Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable
2017-2023
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2014-2023
Loss of TREM2 function impairs phagocytosis and correlates with decreased soluble in biological fluids patients neurodegenerative disorders.
Abstract The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 single 2012 2018 to create recommendations for diagnosis characterization of disease (AD). present document updates research framework response several recent developments. Defining diseases biologically, rather than based syndromic presentation, has long been standard many areas medicine (e.g., oncology), is becoming a unifying concept common all neurodegenerative diseases,...
Abstract Introduction Subjective cognitive decline (SCD) manifesting before clinical impairment could serve as a target population for early intervention trials in Alzheimer's disease (AD). A working group, the Cognitive Decline Initiative (SCD‐I), published SCD research criteria context of preclinical AD. To successfully apply them, number issues regarding assessment and implementation needed to be addressed. Methods Members SCD‐I met identify agree on topics relevant operationalization...
Objective To estimate the risk for developing a defined neurodegenerative syndrome in large cohort of idiopathic REM sleep behavior disorder (IRBD) patients with long follow-up. Methods Using Kaplan-Meier method, we estimated disease-free survival rate from syndromes all consecutive IRBD diagnosed and followed-up our tertiary referal center between November 1991 July 2013. Results The comprises 174 median age at diagnosis 69 years follow-up four years. time was 33.1% five years, 75.7% ten...
TREM2 is an innate immune receptor expressed on the surface of microglia. Loss-of-function mutations are associated with increased risk Alzheimer's disease (AD). a type-1 protein ectodomain that proteolytically cleaved and released into extracellular space as soluble variant (sTREM2), which can be measured in cerebrospinal fluid (CSF). In this cross-sectional multicenter study, we investigated whether CSF levels sTREM2 changed during clinical course AD, cognitively normal individuals...
Background The cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)‐42, total‐tau (T‐tau), and phosphorylated‐tau (P‐tau) demonstrate good diagnostic accuracy for Alzheimer's disease (AD). However, there are large variations in biomarker measurements between studies, within laboratories. Association has initiated a global quality control program to estimate monitor variability of measurements, quantify batch‐to‐batch assay variations, identify sources variability. In this article, we present...
Research increasingly suggests that subjective cognitive decline (SCD) in older adults, the absence of objective dysfunction or depression, may be a harbinger non-normative and eventual progression to dementia. Littl
Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that increases in the cerebrospinal fluid (CSF) and blood individuals with Alzheimer disease (AD). However, it not known whether there are differences GFAP levels across entire AD continuum its performance similar to CSF GFAP.To evaluate plasma throughout continuum, from preclinical dementia, compared GFAP.This observational, cross-sectional study collected data July 29, 2014, January 31, 2020, 3 centers. The...
Abstract Background The cerebrospinal fluid (CSF) biomarkers amyloid beta 1–42, total tau, and phosphorylated tau are used increasingly for Alzheimer's disease (AD) research patient management. However, there large variations in biomarker measurements among within laboratories. Methods Data from the first nine rounds of Association quality control program was to define extent sources analytical variability. In each round, three CSF samples prepared at Clinical Neurochemistry Laboratory...
Abstract Reducing the risk of dementia can halt worldwide increase affected people. The multifactorial and heterogeneous nature late‐onset dementia, including Alzheimer's disease (AD), indicates a potential impact multidomain lifestyle interventions on reduction. positive results landmark Finnish Geriatric Intervention Study to Prevent Cognitive Impairment Disability (FINGER) support such an approach. World‐Wide FINGERS (WW‐FINGERS), launched in 2017 over 25 countries, is first global...